Emerging data suggest Retatru tide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , may represent a significant development for weight management . Initial human tests have demonstrated substantial losses in abdominal tissue, conceivably outperforming current body composition medications . Nevertheless